Anti Inflammatory News and Research

RSS

Caspase-11 identified as regulator of inflammatory pathology in SARS-CoV-2 infections

New findings identify CASP4/11 as detrimental to inflammation and coagulopathy associated with SARS-CoV-2 infection.

28 Sep 2021

Drug treatment decreases risk for severe COVID-19 outcomes in patients with Type 2 diabetes

A type of drug already used to treat obesity and Type 2 diabetes, when taken six months prior to the diagnosis of COVID-19, was associated with a decreased risk of hospitalization, respiratory complications and death in COVID-19 patients with Type 2 diabetes, according to researchers at Penn State College of Medicine.

27 Sep 2021

B cell activating anti-CD73 antibody for the immunotherapy of COVID-19

Despite the advent of numerous vaccines and the discovery of passive monoclonal antibodies for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), there remains an urgent need for definitive therapies for coronavirus disease-2019 (COVID-19) patients.

27 Sep 2021

A review of drugs harmful in COVID-19

In a new study, researchers investigate a number of drugs that are believed to potentially worsen outcomes in patients with COVID-19.

26 Sep 2021

Melanomas that metastasize to the adrenal gland are resistant to checkpoint inhibitors

Recent advances in immunotherapy have allowed doctors at the University of Colorado Cancer Center to more effectively treat melanomas that spread to other parts of the body. Immunotherapy drugs such as checkpoint inhibitors, which are commonly used to treat melanomas, work to strengthen a patient's immune system so that it can prevent a tumor from "turning off" the ability of the immune system to fight it.

24 Sep 2021

Potential covalent SARS-CoV-2 spike protein inhibitors

There remains a significant need for new and effective drugs that can be used to treat COVID-19.

23 Sep 2021

Varying immune responses after single dose of Pfizer and AstraZeneca COVID-19 vaccines

A new preprint describes the significant variation in the early immune response elicited by two of the earliest vaccines to gain emergency authorization against COVID-19.

23 Sep 2021

Neurokinin-1 receptor: a potential drug target for the treatment of COVID-19

An opinion article aims to provide evidence that SP could be the possible factor for initiating the cytokine storm during severe SARS-CoV-2 infection.

21 Sep 2021

Changes in fibrin clot structure contributes to thrombosis risk in severe COVID-19

Researchers from Europe recently demonstrated altered levels of factor XII (FXII) and its activation products in 2 independent cohorts of critically ill patients with COVID-19 compared to patients suffering from severe acute respiratory distress syndrome caused by the influenza virus (acute respiratory distress syndrome (ARDS)-influenza).

21 Sep 2021

First dose of COVID-19 mRNA vaccine (BNT162b2) reduced platelet polyP levels in young females

In a recent study, scientists have tested the hypothesis that indicates the role of polyP in the COVID-19 mRNA vaccine-induced immune responses.

20 Sep 2021

Commonly prescribed cholesterol-lowering drugs could be effective in treating ulcerative colitis

There may be good news for the nearly 1 million people battling ulcerative colitis, a type of inflammatory bowel condition with no real cure: Statins, a commonly prescribed cholesterol-lowering drug, seem to be an effective, if unexpected, treatment for the condition, according to a new Stanford Medicine study.

20 Sep 2021

Higher white matter extracellular free-water related to cognitive dysfunction in lupus patients

Systemic lupus erythematosus (SLE) is an autoimmune disease in which the immune system attacks the body's own tissues, causing widespread inflammation and damage in the affected organs.

18 Sep 2021

COVID-19 and the gut-lung axis

A new study explores the hypothesis that stimulation of the gut could be responsible for the lung inflammation seen in COVID-19, triggered by SARS-CoV-2.

16 Sep 2021

IL-1-Ra autoantibodies observed in high frequency in children with PIMS/MIS-C

Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection typically affects children only mildly, multisystem inflammatory syndrome in children (MIS-C) or pediatric inflammatory multisystem syndrome (PIMS) is a serious but rare complication occurring after infection.

16 Sep 2021

Anti Inflammatory News and Research

Caspase-11 identified as regulator of inflammatory pathology in SARS-CoV-2 infections

Drug treatment decreases risk for severe COVID-19 outcomes in patients with Type 2 diabetes

B cell activating anti-CD73 antibody for the immunotherapy of COVID-19

A review of drugs harmful in COVID-19

Melanomas that metastasize to the adrenal gland are resistant to checkpoint inhibitors

Potential covalent SARS-CoV-2 spike protein inhibitors

Varying immune responses after single dose of Pfizer and AstraZeneca COVID-19 vaccines

Neurokinin-1 receptor: a potential drug target for the treatment of COVID-19

Changes in fibrin clot structure contributes to thrombosis risk in severe COVID-19

First dose of COVID-19 mRNA vaccine (BNT162b2) reduced platelet polyP levels in young females

Commonly prescribed cholesterol-lowering drugs could be effective in treating ulcerative colitis

Higher white matter extracellular free-water related to cognitive dysfunction in lupus patients

COVID-19 and the gut-lung axis

IL-1-Ra autoantibodies observed in high frequency in children with PIMS/MIS-C

Research reveals vital role of protein-coding gene in tumor development and immune therapy response

Flavonoids can potentially help prevent COVID-19-induced diarrhea, study finds

Flu shots and COVID-19 immunity

Researchers explore whether cocoa supplementation can reduce aging

IU researcher uncovers potential new approach for treating pancreatic cancer

NIH researchers develop a detailed cellular map of chronic MS lesions

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News